Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated - guidance (TA377)

NICE Accredited

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
27 January 2016

Abstract

Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet clinically indicated.

 table of NHS England interim treatment regimens gives possible alternative treatment options for use during the COVID-19 pandemic to reduce infection risk. This may affect decisions on using enzalutamide. See the COVID-19 rapid guideline: delivery of systemic anticancer treatments for more details.

Is this guidance up to date?

We reviewed the evidence in January 2019. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.

Commercial arrangement

There is a simple discount patient access scheme for enzalutamide. Contact commercial@astellas.com for details.

Guidance development process

How we develop NICE technology appraisal guidance